Çekiç, ŞükranÖzgür, TanerKaralı, YasinÖzkan, Tanju BaşarırKılıç, S. S.2024-07-232024-07-232018-08-010105-4538https://onlinelibrary.wiley.com/journal/13989995https://hdl.handle.net/11452/43380Bu çalışma, 26-30, Mayıs 2018 tarihlerinde Munich[Almanya]’da düzenlenen Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessScience & technologyLife sciences & biomedicineAllergyImmunologyAllergyImmunologyVedolizumab treatment in patient with Xla, is it safe and efficient?Meeting Abstract000441690405197768769731398-9995